Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
APMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Apnimed, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Apnimed, Inc.
Upcoming catalysts 2
Event history 22
Past FDA Catalysts and PDUFA Decisions
How APMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-21 | AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) | Phase 3 data presentation | Phase 3 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aroxybutynin and Atomoxetine Small MoleculesNCT06566820 | OSA | Phase 3 | ENROLLING BY_INVITATION | 1,280 | Jun 30, 2026 | ||||||
| AD109 Small MoleculesCompletedNCT06400615 | OSA | Phase 3 | COMPLETED | 1,346 | Dec 26, 2024 | ||||||
| AD109 Small MoleculesCompletedNCT04580394 | Obstructive Sleep Apnea | NDA/BLA | COMPLETED | 60 | May 28, 2021 | ||||||
| AD109 Small MoleculesCompletedNCT05071612 | OSA - Obstructive Sleep Apnea | NDA/BLA | COMPLETED | 294 | Aug 3, 2022 | ||||||
| AD113 Small MoleculesCompletedNCT04905979 | Obstructive Sleep Apnea | Phase 2 | COMPLETED | 21 | May 31, 2023 | ||||||
| Dosing 1: Atomoxetine Small MoleculesCompletedNCT05101122 | Obstructive Sleep Apnea | Phase 1/2 | COMPLETED | 15 | Apr 18, 2022 | ||||||
| Period A Small MoleculesCompletedNCT05793684 | OSA | Phase 2 | COMPLETED | 25 | Nov 9, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every APMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SEKHRI PAUL JDirector | BuyOffering | 12,500 12,500 held | $16.00 | 08/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in APMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in APMD for Q2 2026. | ||||
Ownership Trends
APMD Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How APMD ranks across every disease it competes in
APMD News
Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Apnimed reported a $29.5 million net loss for the third quarter of 2026. The company holds $351.8 million in cash to fund operations and a potential U.S. launch of Oxnimbi. The NDA for AD109 remains under FDA review with a PDUFA date of February 28, 2027. Apnimed also presented five abstracts on AD109 data at the CHEST 2026 meeting.
Read more →Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed, Inc. announced the grant of 331,000 stock options to 14 new non-executive employees under its 2026 Inducement Plan. The options have an exercise price of $15.40, matching the closing price on the grant date. This initiative aims to enhance recruitment and retention as the company advances its oral therapy candidate, AD109, for obstructive sleep apnea (OSA).
Read more →Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
Apnimed, Inc. announced that five abstracts have been accepted for presentation at CHEST 2026, including two late-breaking abstracts on their investigational drug AD109 for obstructive sleep apnea. The meeting will feature discussions on the Phase 3 trials and the potential impact of AD109 on OSA management. The FDA is currently reviewing Apnimed's NDA for AD109, with a PDUFA goal date set for February 28, 2027.
Read more →Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Apnimed, Inc. reported its second quarter 2026 financial results, highlighting the FDA's acceptance of its NDA for AD109, proposed as Oxnimbi, with a PDUFA date set for February 28, 2027. The company successfully completed an IPO, raising $220.8 million, and strengthened its leadership team. Oxnimbi aims to be the first oral treatment for obstructive sleep apnea, addressing a significant unmet need in the market.
Read more →Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apnimed, Inc. has successfully closed its upsized initial public offering, raising $220.8 million through the sale of 13.8 million shares. The offering included the full exercise of underwriters' option to purchase additional shares. Apnimed's common stock began trading on the Nasdaq Global Select Market on July 31, 2026. The company is focused on developing novel therapies for sleep-related breathing diseases, particularly obstructive sleep apnea.
Read more →Apnimed Announces Pricing of Upsized Initial Public Offering
Apnimed, a late-stage clinical pharmaceutical company, has announced the pricing of its upsized initial public offering (IPO) of 12 million shares at $16.00 each. The IPO is expected to raise approximately $192 million, with shares set to begin trading on the Nasdaq Global Select Market on July 31, 2026. The offering includes a 30-day option for underwriters to purchase additional shares.
Read more →Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea
Apnimed announced the FDA's acceptance of its New Drug Application for AD109, an investigational oral pill aimed at treating adults with obstructive sleep apnea (OSA). The FDA has set a target action date of February 28, 2027. If approved, AD109 could be the first oral pharmacologic therapy addressing the neuromuscular causes of OSA. The NDA is backed by positive results from Phase 3 clinical trials.
Read more →Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs
Apnimed has appointed Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs. This leadership transition follows the recent appointment of Kevin Lind as CEO and is part of a strategy to prepare the company for growth. Both Kelly and Spector bring significant experience in finance and legal compliance, respectively, as Apnimed advances towards the potential commercialization of its investigational drug AD109 for obstructive sleep apnea.
Read more →Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
Apnimed, Inc. announced that six abstracts, including an oral presentation, will be featured at SLEEP 2026, focusing on pooled Phase 3 data for AD109, its lead candidate for obstructive sleep apnea. The presentations underscore the urgent need for improved awareness and education regarding OSA, highlighting the challenges faced by patients in receiving timely treatment. AD109 aims to simplify intervention and improve patient outcomes in this chronic condition.
Read more →Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
Apnimed has appointed Kevin R. Lind as the new Chief Executive Officer, succeeding founder Lawrence G. Miller, MD, who will take on the role of Vice Chair of the Board. Mr. Lind brings extensive experience in the pharmaceutical industry, including leadership roles that have resulted in successful acquisitions. This leadership change is aimed at implementing the next phase of the company's growth strategy.
Read more →Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
Apnimed announced the publication of its Phase 3 SynAIRgy trial results for AD109, an investigational oral treatment for obstructive sleep apnea (OSA). The study demonstrated significant improvements in oxygenation and reductions in apnea-hypopnea index, supporting AD109's potential as a first-in-class therapy. A New Drug Application has been submitted to the FDA, with a target action date expected in early 2027.
Read more →Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference
Apnimed, Inc. announced multiple presentations at the ATS 2026 International Conference, including three oral presentations and a late-breaking poster. These will showcase findings from the Phase 3 trials of AD109, their lead product candidate for obstructive sleep apnea. The presentations aim to highlight the drug's efficacy in reducing snoring and cardiovascular risks associated with the condition.
Read more →